In order to submit a request for general meeting support for an Annual Meeting, the answers to the following questions must be “Yes”:

☐ Does the activity align with Pfizer’s Primary Areas of Interest? *(listed below)*

☐ Is the activity a live* annual program which serves as a platform for the exchange of new clinical and scientific information and reaches an international, national, regional or local audience?

   *Live CME/CE activities are defined as any activity which incorporates the opportunity for live real-time learner interaction, such as live meetings and live webcasts/webinars*

☐ Is the activity an established part of your organization’s ongoing educational program? If not and it is a new activity, is it clearly based on an assessment of the educational needs of your target audience?

☐ Is the requested grant amount within the following parameters: $50,000 or less for an Annual Meeting with a national/international target audience; $25,000 or less for an Annual Meeting with a regional/local target audience?

<table>
<thead>
<tr>
<th>Application Cycle</th>
<th>To Submit Live Activity Must Start On or After</th>
<th>Decision Communicated By*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 1 - Feb 15</td>
<td>Apr 1</td>
<td>Mar 16</td>
</tr>
<tr>
<td>Mar 1 - Apr 15</td>
<td>July 1</td>
<td>Jun 1</td>
</tr>
<tr>
<td>June 1 - July 15</td>
<td>Oct 1</td>
<td>Aug 31</td>
</tr>
<tr>
<td>Sept 1 - Oct 15</td>
<td>Jan 1, 2021</td>
<td>Nov 30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>If your activity is in.....</th>
<th>Latest* Date to submit to Pfizer is.....</th>
</tr>
</thead>
<tbody>
<tr>
<td>April, May or June 2020</td>
<td>February 15</td>
</tr>
<tr>
<td>July, August or September 2020</td>
<td>April 15</td>
</tr>
<tr>
<td>October, November or December 2020</td>
<td>July 15</td>
</tr>
<tr>
<td>January, February or March 2021</td>
<td>October 15</td>
</tr>
</tbody>
</table>

*This is the latest date to submit. Your request will be reviewed if submitted in an earlier cycle.*

Questions? Email GlobalMedicalGrants@pfizer.com

Updated February 2020
Autoimmune Diseases

Alopecia Areata; Vitiligo
For dermatologists and all healthcare professionals involved in the care and treatment of patients suffering from dermatologic conditions such as alopecia and vitiligo, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and mechanisms-of-action of new medicines for the treatment of dermatologic conditions.

Atopic Dermatitis
Improve the care of patients manifesting atopic dermatitis (AD) by increasing healthcare provider knowledge of the disease state or unmet need and the emerging strategies for treatment of AD.

Inflammation and Immunology – Biosimilars
• Support clinicians’ understanding of complex biosimilar concepts in order to facilitate meaningful discussion of these concepts with patients
• Support the prudent (safe and effective) use of biologic drugs by
  o Increasing awareness of the regulatory framework governing the approval and prescription of biosimilar drugs
  o Increasing awareness of the FDA purple book

Inflammatory Bowel Disease (IBD); Ulcerative Colitis
Improve the care of patients with inflammatory bowel disease (IBD) by increasing healthcare provider knowledge of the emerging strategies for treatment of IBD.

Psoriatic Arthritis
• Improve the care of patients with psoriatic arthritis by increasing healthcare provider knowledge of: (1) the pathophysiology of psoriatic arthritis, (2) the co-management of psoriatic arthritis, (3) the unmet needs in treatment of psoriatic arthritis, and (4) the mechanism of action and clinical data regarding advanced therapies.
• Educate regarding the national and international guidelines for psoriatic arthritis

Rheumatoid Arthritis
• Improve the care of patients with rheumatoid arthritis (RA) by (1) increasing the knowledge of healthcare providers (HCPs) on the pathophysiology of RA, (2) the unmet needs in the treatment of rheumatoid arthritis, and (3) the mechanism of action and clinical data of current advanced therapies

Questions? Email GlobalMedicalGrants@pfizer.com
Updated February 2020
• Address challenges in the management of patients with RA (such as vaccinations, comorbidities, treat to target, etc)

**Cardiovascular Metabolic Risk**

*CVM - blood pressure/hypertension; CVM - cholesterol/hypercholesterolemia; CVM – diabetes; CVM - overweight or physical activity; CVM - General/Non-Specific*

Increase the identification and effective treatment of patients with multiple risk factors for cardiovascular disease and stroke (e.g. hypertension, dyslipidemia, obesity, diabetes) by improving the understanding and clinical practice of healthcare professionals across the globe.

**CVM - Non-Alcoholic Steatohepatitis (NASH)**
The goals are to accelerate innovations in the diagnosis and treatment of NASH, and to improve evidence-based NASH education for health care providers.

**Smoking Cessation/Tobacco Dependence Treatment**
Increase the number of patients who stop smoking by improving the frequency and effectiveness of smoking cessation intervention, including treatment, counseling and support, by healthcare providers.

**Infectious Disease**

**Infectious Disease - Clostridium difficile**

• Increase the understanding of the burden of Clostridium difficile infection
• Increase awareness of ongoing research of preventative vaccines for Clostridium difficile infection

**Infectious Disease - RSV**

• Increase understanding of burden of disease of RSV in infants, children and adults
• Increase understanding of immune response to RSV in infants, children and adults
• Increase awareness of ongoing research of preventative vaccines for RSV

**Infectious Disease- GroupB Strep**

• Increase understanding of burden of disease of GBS in adults
• Increase understanding of immunological biomarkers for GBS infection in infants and adults
• Increase awareness of ongoing research of preventative vaccines for GBS

*Questions? Email GlobalMedicalGrants@pfizer.com*

Updated February 2020
Oncology

Oncology – Biosimilars
Support the prudent (safe and effective) use of biologic drugs in oncology/hematology practice by:

- Increasing clinicians’ understanding of complex biosimilar concepts including the analytical foundation for demonstrating biosimilarity and the regulatory framework governing the approval of biosimilar drugs
- Implementing practical approaches to the incorporation of biosimilars into practice, including protocols, guidelines and pathways
- Discussing the potential for the earlier use of biologics/biosimilars in treatment plans Improving the ability of healthcare professionals to discuss biosimilar options with their patients as part of shared-decision-making
- Overcoming roadblocks to help realize the potential for cost-savings of biosimilars and the overall benefit to reducing healthcare costs in society

Oncology – Breast
For oncologists and all healthcare professionals involved in the care and treatment of patients with breast cancer, increase the awareness and understanding of the latest emerging research, ongoing clinical trials, and mechanisms-of-action of new medicines in particular advances in CDK 4/6 inhibition and PARP inhibition. Other topics of interest include the use of genetic testing to guide treatment decision making, optimizing clinical practice, provider-patient shared decision making, and implementation of clinical pathways.

Oncology – Gastrointestinal – Colorectal Cancer (United States & Canada activities only)

Oncology – General – Research Topics
Through the academic exchange of research and ideas, enhance the discovery and translation of novel cancer therapies, increase scientific understanding of their mechanisms-of-action as well as the efficacy, safety, and potential clinical applicability. Topics of interest include epigenetic modification, signal transduction, cytotoxic potentiators, tyrosine kinase inhibitors, immunotherapy, biosimilars, antibody drug conjugates, biomarkers, and immuno-oncology (IO) specific correlates of safety and efficacy. Also, within IO there is particular interest in advancing the understanding of combinations of novel IO therapies with conventional, targeted, radiation, and existing IO therapies.

Oncology – General - Pediatric Oncology

Questions? Email GlobalMedicalGrants@pfizer.com
Updated February 2020
Oncology – Genitourinary – Prostate
Increase understanding of PARP-inhibitor-class in prostate cancer including mechanisms of action, and genetic/biomarker-testing implications for practice.

Oncology – Genitourinary – Renal Cell Carcinoma (RCC)
For oncologists, urologists and all healthcare professionals involved in the care and treatment of patients with advanced RCC, increase awareness of the evolving treatment landscape and clinical trial results, and also improve clinical competence in applying this information to patient care, especially with respect to treatment selection, sequencing, scheduling, dosing, adjuvant use, use of combination therapies, and management of side effects.

Oncology – Hematologic
Increase understanding in the following areas:

**Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)**
- Risk mitigation and management of toxicities associated with antibody drug conjugates (ADCs)
- Improving outcomes on subsets of Acute Leukemia patients:
  - ALL in relapsed / refractory setting by salvage status, MRD, Ph+, cytogenetics, transplant setting
  - First line treatment landscape for AML patients eligible for intensive induction chemotherapy
  - First line treatment landscape for AML patients ineligible for intensive induction chemotherapy
- Recent developments in 1L therapy for ALL/AML using novel agents (monotherapy, combination, sequencing, cellular therapies)
- Future treatment landscape of ALL and AML especially exploring combination therapy with new novel oral agents

**Chronic Myelogenous Leukemia (CML)**
- The treatment/management of gastrointestinal toxicities and other commonly associated adverse events with TKIs
- Patient adherence strategies with the initiation and maintenance of TKI therapy
- Careful selection of patients for treatment discontinuation/use in real-world setting of treatment discontinuation
- Optimal dose initiation and maintenance of TKI choice based on patient’s medical history and comorbidities (e.g. cardiovascular risk factors)
- Evidence for TKI choice in first and later lines for CP-CML (1L, 2L, 3L, 4L)
- Future treatment landscape in CML specifically exploring combinations with novel therapies

Oncology – Immuno-Oncology

Questions? Email GlobalMedicalGrants@pfizer.com

Updated February 2020
For oncologists and all healthcare professionals involved in the care and treatment of patients with lung, bladder, ovarian, renal, gastric, skin, or head & neck cancers:

- Increase understanding of the rationale for novel IO strategies such as anti-PD-1/PD-L1 therapy
- Increase awareness of when immunotherapy should be considered as a treatment option for patients to include selection, sequencing, and combinations
- Improve ability to manage associated IO treatment issues including side effects and progression

**Oncology – Lung**
For oncologists, nurses, pharmacists, pulmonologists, pathologists, surgeons, interventional radiologists, and all healthcare professionals involved in the care and treatment of patients with NSCLC, increase the awareness and understanding of the importance of treating patients based on the timely results of molecular testing (e.g. ALK, EGFR, ROS1) and improving management of adverse events of biomarker-driven therapies in order to optimize patient outcomes.

**Oncology – Skin** - Melanoma (United States & Canada activities only)

**Pain – Osteoarthritis**
*Chronic Pain Associated with Osteoarthritis (Pfizer/Lilly alliance)*
Please see below under ‘Clinical Areas Reviewed through Joint Alliances/Partnerships.’

**Rare Diseases**

- **Achondroplasia**
- **Amyotrophic Lateral Sclerosis (ALS)**
- **Chronic Inflammatory Demyelinating Polyneuropathy**
- **Duchenne Muscular Dystrophy**
  Close knowledge gaps regarding the progression of the pathophysiology and clinical manifestations.

**Endocrine - Acromegaly**
- Improve the *emerging science* knowledge base of health care providers, educators, and third party payers working in the area of acromegaly.

*Questions? Email* GlobalMedicalGrants@pfizer.com
*Updated February 2020*
• Improve the care of patients with acromegaly by:
  o Increasing awareness of the signs, symptoms and comorbidities of acromegaly in order to decrease the time to diagnosis from onset of the disease.
  o Increasing the understanding of acromegaly and the clinical guidelines related to the evaluation and management of acromegaly
  o Increasing awareness of currently available treatment options
  o Increasing the understanding of the importance of monitoring biochemical parameters, signs and symptoms, and quality of life to ensure patients are optimally treated.

**Endocrine - Growth Hormone Deficiency**
• Improve the knowledge base of health care providers, educators, and third party payers working in the area of GHD.
• Improve the understanding of the safety and efficacy of growth hormone (GH) administered once-daily in managing patients with short stature.
• Improve the understanding of the relationship between adherence and treatment outcomes.
• Increase awareness of the emerging science of long-acting growth hormone to improve the understanding of their efficacy, safety, and potential clinical applicability.

**Friedreich’s Ataxia**
Improve the understanding of the progression of the pathophysiology and clinical manifestations.

**Focal Segmental Glomerulosclerosis**

**Frontotemporal dementia (FTD, Pick’s Disease)**

**Gene Therapy**
Close knowledge gaps regarding gene therapy applications and clinical development and conduct of clinical trials.

**Hemophilia**
Facilitate enhanced coordination of care and communications between patients with clotting or bleeding disorders, including hemophilia, and their doctors, and ensure practitioners know how to safely treat and monitor these patients.

**Hereditary Angioedema**

**Questions?** Email GlobalMedicalGrants@pfizer.com
Updated February 2020
Phenylketonuria (PKU)

Pulmonary Arterial Hypertension (PAH)
Improve the understanding of the progression of the pathophysiology and clinical manifestations.

Rare Cardiomyopathy

Sickle Cell Disease
Improve healthcare provider’s knowledge of diagnosis and treatment of sickle cell disease and facilitate enhanced coordination of care and communication between patients with sickle cell disease and healthcare providers.

Lysosomal Storage Diseases
Improve positive outcomes in patients with Lysosomal Storage Diseases by facilitating enhanced coordination of care and communication between multidisciplinary teams of healthcare professionals, ensuring practitioners know how to safely treat and monitor patients.

Myotonic Dystrophy (DM1)
Improve the understanding of the progression of the pathophysiology and clinical manifestations.

TTR Amyloidosis: Transthyretin Cardiomyopathy (ATTR-CM)
Improve the care of patients by:
- Closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment paradigms.
- Addressing barriers to diagnosis and strategies that reduce burdens for patients and providers along the pathway to diagnosis
- Exploring strategies that empower patients to play an active role in understanding TTR amyloidosis and available diagnostic and treatment options
- Increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR and wild-type ATTR subtypes in the modern era
- Increasing awareness of at risk and undiagnosed populations with TTR amyloidosis with a focus on improving strategies that facilitate the diagnosis of patients early in the disease course before overt cardiomyopathy has ensued
- Increasing awareness of bone radiotracer scintigraphy as a non-invasive alternative to invasive endomyocardial biopsy for the diagnosis of TTR cardiac amyloidosis in select patients

Questions? Email GlobalMedicalGrants@pfizer.com
Updated February 2020
• Supporting the dissemination of information related to the study of emerging treatment options to improve patient important outcomes in TTR amyloidosis
• Supporting the development of cardiac amyloid centers that provide leadership, best practices, support and/or training of HCPs within a multidisciplinary team environment in order to improve the quality of care for cardiac amyloidosis patients.

Vaccine Preventable Diseases
Improve immunization across the life span by addressing perceptions of society and healthcare providers related to pediatric, adolescent and adult immunizations.

Vaccine Preventable Disease – Pneumococcal
Improve the care of pediatric patients by:
• Highlighting the disparity between family physicians and pediatricians in adherence to recommended childhood vaccination schedule
• Addressing barriers to vaccination and series completion with a focus on lower education and socioeconomic groups and other under-immunized populations including rural and inner-city settings as well as barriers to vaccination within the current medical system, including bureaucratic structure issues and HCP availability
• Assessing how barriers can be overcome in the current medical system where making changes in the practice is often difficult given the current bureaucratic structure of many practices and the demands on HCP time
• Exploring gaps in the healthcare system that negatively impact the burden of invasive pneumococcal disease and search for ways to minimize these gaps through educational programs

Improve the care of adult patients by:
• Increasing the awareness of the changing epidemiology of pneumococcal pneumonia in adults
• Increasing the awareness and understanding of adult pneumococcal vaccination guidelines including the limitations of the guidelines
• Increasing the percentage of adults receiving national guideline and medical society recommended immunizations

Vaccine Preventable Disease – Meningococcal
Optimize the prevention of meningococcal disease by:
• Enhancing understanding of changing meningococcal epidemiology including mortality, morbidity and long-term consequences of meningococcal disease
• Increasing awareness of the risk of meningococcal disease for all ages
• Improving meningococcal vaccine recommendation implementation and vaccine uptake including:
  o Risk of meningococcal disease by healthcare practitioners

Questions? Email GlobalMedicalGrants@pfizer.com
Updated February 2020
o Improving access to meningococcal vaccines
o Understanding the preferences and choices of parents and adolescents towards meningococcal vaccines and disease prevention

Vaccine Preventable Disease- Public Health and General Vaccinology

Women's Health/Menopause
Support education where concepts, issues and advances in women’s reproductive and/or post-reproductive health care are discussed with a goal of improving individual and population health outcomes. Areas of particular interest include (but are not limited to) an individualized approach to the management of menopause and a women’s health continuum of care across the lifespan.

Support for the Professions
This category supports live, MAJOR national and regional conferences whose target audience includes professionals who work in, develop, implement and/or support CME/CE/CPD and QI for healthcare professionals; and live, MAJOR conferences of societies whose members include under-represented or minority healthcare professionals. NOTE: If an organization requests and receives funding through the IGLC grants portal, they are no longer eligible for funding directly from a Pfizer Country Office, or regional office.

Support for Health Outcomes
This category supports live, MAJOR, national and regional conferences whose target audience includes professionals who work in, develop and/or support initiatives that advance and enable better health outcomes across the continuum of patient care through:

- Initiatives that drive collaboration and innovation to ensure immediate access to relevant and personal: medical information needed to inform healthcare decisions
- Organizations functioning in the areas of Health Data and Informatics to advance understanding of and/or generate evidence that promotes better health decisions.

*****

Questions? Email GlobalMedicalGrants@pfizer.com
Updated February 2020
Clinical Areas Reviewed through Joint Alliances/Partnerships

Please note, in order to apply to any of the Joint Alliance/Partnership programs listed below your organization must also meet Pfizer’s eligibility requirements. Click here to view further details about eligibility.

Chronic Pain Associated with Osteoarthritis
Pfizer and Lilly are working together on grants in support of medical education in chronic pain associated with osteoarthritis and chronic low back pain. We are committed to supporting innovative, independent medical education for healthcare professionals. All grant applications should be submitted to Pfizer only, to avoid application duplication. To apply now, go to our grant management system.

Diabetes Treatment
Pfizer and Merck are working together on grants in support of diabetes treatment-related education. The goal of this education is to increase the understanding of SGLT2 inhibition in the management of diabetes.

All grant applications should be submitted to Merck only. Please refer to the Merck website for information.

Oncology - Nonsteroidal Anti-Androgen Treatment of Prostate
In the United States, Pfizer and Astellas are working together on grants in support of prostate cancer-related education. The goal of this education is to increase the ability of healthcare professionals to consistently provide their patients with optimal guidelines-based care.

All grant applications should be submitted to Astellas only. Please refer to the Astellas website for information.

Thrombosis Prevention / Anti-coagulation
Pfizer and Bristol Myers Squibb (BMS) are working together on grants in support of thrombosis / anticoagulation-related education. The goal of this education is to decrease the unmet medical needs in the prevention and treatment of venous and arterial thrombosis.

All grant applications should be submitted to Bristol Myers Squibb only. Please refer to the Bristol Myers Squibb website for information.

Questions? Email GlobalMedicalGrants@pfizer.com
Updated February 2020